What is the recommended management for DVT in a patient without kidney impairment?

The recommended management for Deep Vein Thrombosis (DVT) in a patient without kidney impairment would typically involve the use of direct oral anticoagulants (DOACs), with rivaroxaban being one of the preferred choices. Administering rivaroxaban at a dose of 15 mg for 21 days, followed by a maintenance dose, aligns with current guidelines for the treatment of DVT. This approach allows for the rapid establishment of anticoagulation, reducing the risk of complications such as pulmonary embolism, while also providing a simplified regimen that does not require regular monitoring of INR, which is necessary with warfarin therapy.

This method is favored due to the ease of use and effective pharmacodynamics, making it a suitable choice for managing DVT in the specified patient group. The transition to maintenance dosing after the initial treatment period further solidifies its role as a practical and effective management strategy.